-
-
-
-
-
-
-
Ligand Pharma (LGND) Tops Q3 EPS by 116c ; Offers Guidance
-
-
-
-
-
-
-
Ligand Pharma (LGND) Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
-
-
-
-
-
-
-
Ligand Pharma (LGND) Tops Q4 EPS by 9c ; Offers Guidance
-
-
-
-
-
-
-
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
-
-
-
-
-
-
-
Ligand Pharma (LGND) Tops Q1 EPS by 36c, provides guidance
-
-
-
-
-
-
-
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
-
-
-
-
-
-
-
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

